IRB #

STUDY00015218

Title

A Phase 3 Prospective, Randomized, Double-Blind, Multi-Center, Study Of The Efficacy And Safety Of Lanreotide Autogel/ Depot 120mg Plus BSC Vs Placebo Plus BSC For Tumor Control In Subjects With Well-Differentiated, Metastatic And/Or Unresectable Typical Or Atypical Lung Neuroendocrine Tumors

Principal Investigator

Jeremy Cetnar

Study Purpose

To evaluate the effectiveness and safety of lanreotide autogel in patients with neuroendocrine tumor (NET) of the lungs when compared to placebo

Medical Condition(s)

1. metastatic lung neuroendocrine tumors
2. metastatic lung NET

Eligibility Criteria

1. Male or Female age 18 or older
2. Confirmed neuroendocrine tumor of lung
3. Metastatic and/or cannot be surgically removed

Age Range

18 - 100

Healthy Volunteers Needed

No

Duration of Participation

Treatment will continue until your disease progresses, you can't tolerate the treatment, or you and/or your doctor decide to stop treatment. After that participants will be followed for the duration of the study or the patient no longer would like to consent to being followed.

Minors Included

No

Contact

Knight Clinical Trials Information Line
503-494-1080
Knight@ohsu.edu

Sponsor

Ipsen Biopharmaceuticals

Recruitment End

02/28/2030

Compensation Provided

No


Go Back